3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
28
Melanoma
9
Triple Negative Breast Neoplasms
8
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Colorectal Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Sarcoma
3
Ovarian Neoplasms
3
Neoplasms
3
Mesothelioma
3
Lymphoma
3
Head and Neck Neoplasms
3
Adenocarcinoma of Lung
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
NSCLC
2
Liver Neoplasms
2
Kidney Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Interventions
pembrolizumab
4
Trastuzumab
2
Interleukin-12 Subunit p35
2
Drug Therapy
2
tipifarnib
1
spartalizumab
1
seribantumab
1
pertuzumab
1
motexafin lutetium
1
entinostat
1
Thalidomide
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Ipilimumab
1
Interleukin-12
1
Injections, Subcutaneous
1
Immunotherapy
1
Gemcitabine
1
Fluorouracil
1
Fentanyl
1
Escitalopram
1
Erlotinib Hydrochloride
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
spartalizumab
×
Thoracic
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts